Key Drivers
- Strong Liquidity
- Persistent Cash Burn
- High Sales Valuation
AIAI Summary
IMTX has shifted from a cash-supported biotech story to a late-stage, high-binary PRAME catalyst play: the $521M balance sheet gives it runway into key 2026 readouts, but the stock's real upside now depends almost entirely on SUPRAME and broader PRAME data being strong enough to justify a 2027 commercialization path.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Cash Burn
- •High Sales Valuation
IMTX has a very strong cash position and low leverage, but persistent operating losses, negative free cash flow, and a rich sales-based valuation remain the main risks.
Price Behavior
Key Price Behavior Insights:
- •Range-bound action
- •Firm support zone
- •Failed breakout
IMTX has been range-bound over the last month, with support at $10.80-$10.90 and resistance at $11.40-$11.60, while the failed push above $11.50 signals fading momentum and a neutral to slightly cautious short-term outlook.
The move above $11.50 failed to hold, and price drifted back from a recent high near $11.60
Sentiment & News
Key News Insights:
- •PRAME Progress
- •ASCO Visibility
- •Cash Runway
Immatics advanced its PRAME pipeline with encouraging clinical updates and ASCO visibility, while strong cash runway was offset by a wider-than-expected Q1 loss and missed revenue.
The updates are modestly positive for long-term pipeline value, but near-term sentiment may stay mixed until stronger clinical and financial execution is shown
Similar Companies in Healthcare
Other companies in the same sector with AI ratings